ArticleInternational journal of molecular sciences2026
Nucleolaron1511 and Nucleolaron1510 Facilitate Effective Intracellular Delivery of Azami Green Protein in HeLa Cells.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intracellular delivery of large macromolecules remains a significant challenge in both therapeutic and research contexts. This study investigates two novel chimeric cell-penetrating peptides, Nucleolaron1511 (Nuc1511) and Nucleolaron1510 (Nuc1510), with the aim of evaluating their capacities to deliver the fluorescent protein Azami Green (AG) into HeLa cells via genetic fusion. Cellular uptake of TAMRA-labeled Nuc1510 was assessed by fluorescence microscopy at multiple time points. Delivery efficiency of AG-Nuc1511 and AG-Nuc1510 fusion proteins was evaluated by fluorescence microscopy and flow cytometry, and cytotoxicity was assessed across a range of concentrations using the MTT assay. TAMRA-Nuc1510 successfully penetrated HeLa cells within one hour of treatment, with signal detected in both cytoplasmic and nuclear compartments. Flow cytometry quantification revealed that fusion with Nuc1511 increased intracellular AG fluorescence by over 80-fold relative to unconjugated AG, while Nuc1510 fusion yielded approximately a 9-fold increase. Neither peptide exhibited significant cytotoxicity at concentrations used in the delivery assays. These findings establish Nuc1511 and Nuc1510 as effective CPPs capable of facilitating intracellular protein delivery via genetic fusion, with favorable safety profiles, representing promising candidates for protein-based intracellular delivery in research and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.